ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 256 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $718,811 | -21.0% | 20,163 | +2.2% | 0.01% | -14.3% |
| Q2 2023 | $909,776 | +17.6% | 19,722 | +2.2% | 0.01% | 0.0% |
| Q1 2023 | $773,810 | -11.0% | 19,297 | +2.8% | 0.01% | -12.5% |
| Q4 2022 | $869,799 | +16.3% | 18,774 | +4.0% | 0.01% | 0.0% |
| Q3 2022 | $748,000 | -29.8% | 18,053 | +1.1% | 0.01% | -20.0% |
| Q2 2022 | $1,066,000 | -16.1% | 17,863 | +2.1% | 0.01% | 0.0% |
| Q1 2022 | $1,271,000 | -12.9% | 17,504 | +0.9% | 0.01% | -9.1% |
| Q4 2021 | $1,459,000 | -7.4% | 17,345 | -0.7% | 0.01% | -15.4% |
| Q3 2021 | $1,575,000 | -4.5% | 17,463 | +1.0% | 0.01% | 0.0% |
| Q2 2021 | $1,649,000 | -20.8% | 17,289 | -5.5% | 0.01% | -27.8% |
| Q1 2021 | $2,083,000 | -9.9% | 18,295 | +9.6% | 0.02% | -14.3% |
| Q4 2020 | $2,311,000 | +64.1% | 16,693 | -2.5% | 0.02% | +50.0% |
| Q3 2020 | $1,408,000 | +45.0% | 17,128 | +38.0% | 0.01% | 0.0% |
| Q2 2020 | $971,000 | +69.8% | 12,413 | -3.7% | 0.01% | +40.0% |
| Q1 2020 | $572,000 | – | 12,884 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |